Voyager Therapeutics Inc

NASDAQ:VYGRUnited States

Voyager Therapeutics, Inc. is a gene therapy company, which is focused on developing treatments and platform technologies. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. It is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. It has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. It also focuses on tauopathies and indications in neuro-oncology.

Contact Information

Headquarters

64 SIDNEY STREETCAMBRIDGE, MA, United States 02139

Phone

857-259-5340

Fax

302-655-5049

Executives

Independent Chairman of the Board

Michael Higgins

Director

Alfred Sandrock

Chief Financial Officer

Peter Pfreundschuh

Chief Operating Officer

Robin Swartz

Senior Vice President, General Counsel

Robert Hesslein